The U.S. Food and Drug Administration has granted approval for an Abbreviated New Drug Application (ANDA) numbered 076346 submitted by Teva Pharmaceuticals USA, Inc. for the loop diuretic torsemide.
The approved product is an oral tablet marketed under the brand name TORSEMIDE, available in four strengths – 5 mg, 10 mg, 20 mg, and 100 mg – each designated as prescription‑only.
The submission history includes an original filing on 30 May 2003, subsequent manufacturing (CMC) and labeling supplements, with the most recent labeling supplement submitted on 4 May 2020.
FDA labeling classifies torsemide as a loop diuretic that increases diuresis at the loop of Henle.
法规动态2026年8月26日•1 分钟阅读
FDA Approves Teva Torsemide Generic Tablets (ANDA 076346)
The FDA has approved Teva Pharmaceuticals’ ANDA 076346 for torsemide oral tablets in 5 mg, 10 mg, 20 mg and 100 mg strengths, prescription‑only.
由 PharmaCountry 团队整理 · 来源: FDA.gov
评分
(0)
(0)
(0)
(0)
(0)
留下您的评分